On 17 Jan 2020, Merus N.V. (NASDAQ: MRUS) spotted trading -18.95% off 52-week high price. On the other end, the stock has been noted 54.36% away from the low price over the last 52-weeks. The stock changed -4.34% to recent value of $16.98. The stock transacted 95529 shares during most recent day however it has an average volume of 122.54K shares. The company has 25.37M of outstanding shares and 23.72M shares were floated in the market.
Syros Pharmaceuticals (SYRS) recently stated financial results for the quarter ended September 30, 2019.
“At Syros, we are focused where we believe we have the greatest potential to make a profound difference for patients by developing small-molecule medicines to control the expression of genes,” stated Nancy Simonian, M.D., Chief Executive Officer of Syros. “This quarter, we made important strides on that front. We stated strong clinical data from our Phase 2 trial of SY-1425 in RARA-positive newly diagnosed unfit AML patients, showing that our discovery of this novel patient subset is translating into clinical benefit. Building on our leadership in selective CDK7 inhibition, we presented new preclinical data on SY-5609 in models of difficult-to-treat solid tumors, highlighting its best-in-class potential as an oral CDK7 inhibitor. These data inform our clinical development plans for both programs and provide us a clear path to make meaningful progress across our pipeline next year. We look forward to reporting potential proof-of-concept data in 2020 for SY-1425 in relapsed or refractory RARA-positive AML patients and to initiating a Phase 1 study of SY-5609 in select solid tumors in the first quarter of 2020.”
Third Quarter 2019 Financial Results:
Syros had cash, cash equivalents and marketable securities of $108.1M as of September 30, 2019, as contrast with $99.7M in December 31, 2018. This increase in cash reflects aggregate net proceeds of about $65.0M from Syros’ two concurrent underwritten public offerings, which closed in April 2019.
For the third quarter of 2019, Syros stated a net loss of $19.8M, or $0.47 per share, contrast to a net loss of $15.7M, or $0.47 per share, for the same period in 2018.
Revenues were $0.6M for the third quarter of 2019, as contrast to $0.4M for the third quarter of 2018. Revenues in both the third quarter of 2019 and the third quarter of 2018 were earned under Syros’ alliance with Incyte Corporation.
Research and development (R&D) expenses were $15.9M for the third quarter of 2019, as contrast to $12.9M for the same period in 2018. This increase was primarily attributable to continued advancement of the Company’s existing clinical trials and advancement of its preclinical programs, including completing SY-5609 IND-enabling studies.
General and administrative (G&A) expenses were $5.0M for the third quarter of 2019, as contrast to $3.9M for the same period in 2018. This increase was primarily attributable to a raise in employee-related expenses.
Merus N.V. (MRUS) Its earnings per share (EPS) expected to touch remained 67.70% for this year. According to the most recent quarter its current ratio was 5.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 10.81% from the mean of 20 days, 7.93% from mean of 50 days SMA and performed 9.17% from mean of 200 days price. Company’s performance for the week was 16.54%, 3.85% for month and YTD performance remained 20.60%.